Peyton V. Warp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peyton V. Warp has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
David P. Serota
Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA
2 shared publicationsHansel E. Tookes
Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA
2 shared publicationsIrasema Cruz
IDEA Exchange, University of Miami Miller School of Medicine, Miami, USA
2 shared publicationsKatrina Ciraldo
Department of Family Medicine, University of Miami Miller School of Medicine, Miami, USA
2 shared publicationsMaia Hauschild
Department of Medical Education, University of Miami Miller School of Medicine, Miami, USA
2 shared publicationsScott A. Elman
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida
2 shared publications
Latest Publications
- 23 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study
In this retrospective cohort study of 202 patients at the University of Miami, we assessed whether treatment lapses influence outcomes in early-stage mycosis fungoides. We found that patients who had treatment lapses were more likely to experience worsening of their disease and transformation to a more aggressive form. These findings suggest that continuity of treatment, even with low-intensity regimens, may be important for long-term disease control.
- 23 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study
In this retrospective cohort study of 202 patients at the University of Miami, we assessed whether treatment lapses influence outcomes in early-stage mycosis fungoides. We found that patients who had treatment lapses were more likely to experience worsening of their disease and transformation to a more aggressive form. These findings suggest that continuity of treatment, even with low-intensity regimens, may be important for long-term disease control.
- Open Access
- 17 August 2026
- Published by Wiley in JEADV Clinical Practice
Vitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification
Background: Vitiligo is an autoimmune disorder characterized by CD8+ T cell‐mediated melanocyte destruction and a pro‐inflammatory immune milieu. Despite frequent use of ultraviolet‐based phototherapy, emerging evidence suggests that vitiligo may paradoxically confer a reduced risk of skin cancer. Clarifying this association may provide insight into tumor immune surveillance and inform risk assessment in patients with vitiligo. Objectives: To evaluate the association between vitiligo and the risk of melanoma and non‐melanoma skin cancers (NMSC), and to assess the potential impact of phototherapy exposure on skin cancer risk. Methods: A PRISMA‐compliant systematic review and meta‐analysis searched PubMed, Scopus, Embase, and ClinicalTrials.gov through January 2026 for studies comparing skin cancer incidence in patients with vitiligo versus controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using Hartung‐Knapp random‐effects models, with assessment of heterogeneity and publication bias. Results: Fourteen studies were included (454,307 vitiligo patients; 3,583,147 controls), of which nine were eligible for meta‐analysis. Vitiligo was associated with lower odds of melanoma (OR 0.43; 95% CI, 0.16–1.13), with consistent inverse associations across sensitivity analyses. A similar inverse trend was observed for NMSC overall (OR 0.29; 95% CI, 0.06–1.49). Squamous cell carcinoma risk was significantly reduced (OR 0.76; 95% CI 0.57–0.99; p = 0.045), while basal cell carcinoma showed a non‐significant inverse association (OR 0.54; 95% CI, 0.26–1.11). Phototherapy exposure was associated with higher point estimates for melanoma (OR 1.87; 95% CI 0.53–6.54) and NMSC (OR 1.46; 95% CI, 0.37–5.69), although neither association reached statistical significance. Funnel plots and Egger's testing did not detect publication bias. Conclusions: Vitiligo was associated with lower odds of melanoma and NMSC, with a statistically significant reduction for squamous cell carcinoma. Phototherapy exposure showed higher but non‐significant point estimates. These findings provide a benchmark for baseline cancer risk in vitiligo and may inform safety monitoring of phototherapy and emerging immunomodulatory therapies. PROSPERO number: CRD42024619708.
- 17 August 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessVitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification
Background: Vitiligo is an autoimmune disorder characterized by CD8+ T cell‐mediated melanocyte destruction and a pro‐inflammatory immune milieu. Despite frequent use of ultraviolet‐based phototherapy, emerging evidence suggests that vitiligo may paradoxically confer a reduced risk of skin cancer. Clarifying this association may provide insight into tumor immune surveillance and inform risk assessment in patients with vitiligo. Objectives: To evaluate the association between vitiligo and the risk of melanoma and non‐melanoma skin cancers (NMSC), and to assess the potential impact of phototherapy exposure on skin cancer risk. Methods: A PRISMA‐compliant systematic review and meta‐analysis searched PubMed, Scopus, Embase, and ClinicalTrials.gov through January 2026 for studies comparing skin cancer incidence in patients with vitiligo versus controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using Hartung‐Knapp random‐effects models, with assessment of heterogeneity and publication bias. Results: Fourteen studies were included (454,307 vitiligo patients; 3,583,147 controls), of which nine were eligible for meta‐analysis. Vitiligo was associated with lower odds of melanoma (OR 0.43; 95% CI, 0.16–1.13), with consistent inverse associations across sensitivity analyses. A similar inverse trend was observed for NMSC overall (OR 0.29; 95% CI, 0.06–1.49). Squamous cell carcinoma risk was significantly reduced (OR 0.76; 95% CI 0.57–0.99; p = 0.045), while basal cell carcinoma showed a non‐significant inverse association (OR 0.54; 95% CI, 0.26–1.11). Phototherapy exposure was associated with higher point estimates for melanoma (OR 1.87; 95% CI 0.53–6.54) and NMSC (OR 1.46; 95% CI, 0.37–5.69), although neither association reached statistical significance. Funnel plots and Egger's testing did not detect publication bias. Conclusions: Vitiligo was associated with lower odds of melanoma and NMSC, with a statistically significant reduction for squamous cell carcinoma. Phototherapy exposure showed higher but non‐significant point estimates. These findings provide a benchmark for baseline cancer risk in vitiligo and may inform safety monitoring of phototherapy and emerging immunomodulatory therapies. PROSPERO number: CRD42024619708.
- 21 January 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (5) , 1547-1549
Distinguishing acute skin failure in the critically ill: A retrospective cohort study
- 21 January 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (5) , 1547-1549
Distinguishing acute skin failure in the critically ill: A retrospective cohort study
- Open Access
Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia
Chemotherapy-induced neutropenia (CIN) and chemotherapy-induced alopecia (CIA) are significant toxicities affecting cancer patients. CIN is a potentially fatal complication of chemotherapy caused by myelosuppression and increased infection susceptibility, while CIA, although not fatal, severely affects treatment adherence and mental health. This study provides a comprehensive comparative analysis of CIN and CIA, focusing on patient, disease, treatment, and genetic risk factors. Key risk factors for CIN and CIA include age, poor performance status, body mass index (BMI), laboratory abnormalities, and pre-existing comorbidities. Both toxicities were significantly associated with breast cancer patients, although CIN patients were more likely to have hematological cancer, and CIA patients were more likely to have solid tumors. Notably, anthracyclines, alkylators, and taxanes frequently induce both toxicities, although their timelines and clinical implications differed. There was no clear overlap between genetic predispositions and toxicities beyond single-nucleotide polymorphisms (SNPs) in the ABCB1 gene. This is the first study to directly compare CIN and CIA, offering insights into personalized oncology care. Understanding the risk factors implicated in the development of CIN and CIA will enable physicians to manage patient outcomes.
Open AccessParallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia
Chemotherapy-induced neutropenia (CIN) and chemotherapy-induced alopecia (CIA) are significant toxicities affecting cancer patients. CIN is a potentially fatal complication of chemotherapy caused by myelosuppression and increased infection susceptibility, while CIA, although not fatal, severely affects treatment adherence and mental health. This study provides a comprehensive comparative analysis of CIN and CIA, focusing on patient, disease, treatment, and genetic risk factors. Key risk factors for CIN and CIA include age, poor performance status, body mass index (BMI), laboratory abnormalities, and pre-existing comorbidities. Both toxicities were significantly associated with breast cancer patients, although CIN patients were more likely to have hematological cancer, and CIA patients were more likely to have solid tumors. Notably, anthracyclines, alkylators, and taxanes frequently induce both toxicities, although their timelines and clinical implications differed. There was no clear overlap between genetic predispositions and toxicities beyond single-nucleotide polymorphisms (SNPs) in the ABCB1 gene. This is the first study to directly compare CIN and CIA, offering insights into personalized oncology care. Understanding the risk factors implicated in the development of CIN and CIA will enable physicians to manage patient outcomes.
- Open Access
- 9 May 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (7)
Prolonged depletion of profilin 1 or F-actin causes an adaptive response in microtubules
In addition to its well-established role in actin assembly, profilin 1 (PFN1) has been shown to bind to tubulin and alter microtubule growth. However, whether PFN1’s predominant control over microtubules in cells occurs through direct regulation of tubulin or indirectly through the polymerization of actin has yet to be determined. Here, we manipulated PFN1 expression, actin filament assembly, and actomyosin contractility and showed that reducing any of these parameters for extended periods of time caused an adaptive response in the microtubule cytoskeleton, with the effect being significantly more pronounced in neuronal processes. All the observed changes to microtubules were reversible if actomyosin was restored, arguing that PFN1’s regulation of microtubules occurs principally through actin. Moreover, the cytoskeletal modifications resulting from PFN1 depletion in neuronal processes affected microtubule-based transport and mimicked phenotypes that are linked to neurodegenerative disease. This demonstrates how defects in actin can cause compensatory responses in other cytoskeleton components, which in turn significantly alter cellular function.
- 9 May 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (7)
Open AccessProlonged depletion of profilin 1 or F-actin causes an adaptive response in microtubules
In addition to its well-established role in actin assembly, profilin 1 (PFN1) has been shown to bind to tubulin and alter microtubule growth. However, whether PFN1’s predominant control over microtubules in cells occurs through direct regulation of tubulin or indirectly through the polymerization of actin has yet to be determined. Here, we manipulated PFN1 expression, actin filament assembly, and actomyosin contractility and showed that reducing any of these parameters for extended periods of time caused an adaptive response in the microtubule cytoskeleton, with the effect being significantly more pronounced in neuronal processes. All the observed changes to microtubules were reversible if actomyosin was restored, arguing that PFN1’s regulation of microtubules occurs principally through actin. Moreover, the cytoskeletal modifications resulting from PFN1 depletion in neuronal processes affected microtubule-based transport and mimicked phenotypes that are linked to neurodegenerative disease. This demonstrates how defects in actin can cause compensatory responses in other cytoskeleton components, which in turn significantly alter cellular function.
- Open Access
- 15 March 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-5
A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA
Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida. Case presentation: A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic. Conclusions: Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.
- 15 March 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-5
Open AccessA confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA
Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida. Case presentation: A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic. Conclusions: Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.
- Open Access
- 26 July 2023
- Published by Springer Nature in Research Square
A Confirmed Case of Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Miami, Florida, USA
Background Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the street drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who inject drugs (PWID). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida.Case Presentation A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at the IDEA Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits are discussed below. Wound outcomes are unknown as the patient has not returned to clinic.Conclusions Many PWID at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system. There is an urgent need for access to XTS for PWID and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.
- 26 July 2023
- Published by Springer Nature in Research Square
Open AccessA Confirmed Case of Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Miami, Florida, USA
Background Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the street drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who inject drugs (PWID). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida.Case Presentation A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at the IDEA Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits are discussed below. Wound outcomes are unknown as the patient has not returned to clinic.Conclusions Many PWID at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system. There is an urgent need for access to XTS for PWID and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.